氯法齐明对结核分枝杆菌的抗菌活性延迟:体外与体内研究
该研究系统评估了氯法齐明对结核分枝杆菌的早期杀菌活性(EBA),体外采用低于至高于MIC 4倍的浓度,体内采用感染BALB/c小鼠1.5至100 mg/kg/天的剂量。结果显示氯法齐明在体外和体内第一周均无杀菌活性,第二周才出现浓度依赖的抗菌活性,且体内抗菌活性与剂量无显著相关。
要点
- 氯法齐明体外第一周无杀菌活性,第二周呈浓度依赖抗菌活性。
- 体内第一周无杀菌活性,第二周抗菌活性有限且与剂量无关。
- 氯法齐明的延迟抗菌活性可能主要与其作用机制有关。
核心结论
- 氯法齐明对结核分枝杆菌的抗菌活性延迟,可能更多源于其作用机制而非宿主相关因素。
研究设计与样本
- 体外评估氯法齐明在MIC 4倍以下至4倍以上浓度范围的14天早期杀菌活性(EBA),以异烟肼为阳性对照。
- 体内评估感染BALB/c小鼠给予1.5至100 mg/kg/天氯法齐明的14天EBA,并测定血清氯法齐明水平,以异烟肼为阳性对照。
主要发现
- 体外:氯法齐明在所试任何浓度下第一周均无杀菌活性,第二周呈现浓度依赖性抗菌活性。
- 体内:氯法齐明在所试任何剂量下第一周均无杀菌活性,第二周观察到有限的抗菌活性。
- 血清氯法齐明水平呈明显剂量依赖性,但抗菌活性与给药剂量无显著相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The anti-leprosy drug clofazimine has been shown to have antimicrobial activity against Mycobacterium tuberculosis and has been associated with treatment-shortening activity in both clinical and preclinical studies of TB chemotherapy. However, a reported lack of early bactericidal activity (EBA) in TB patients has raised questions regarding the usefulness of clofazimine as an anti-TB drug. Our objective was to systematically evaluate the EBA of clofazimine in vitro and in vivo to provide insight into how and when this drug exerts its antimicrobial activity against M. tuberculosis. METHODS: We evaluated the 14 day EBA of clofazimine (i) in vitro at concentrations ranging from 4 times below to 4 times above the MIC for M. tuberculosis and (ii) in vivo in infected BALB/c mice at doses ranging from 1.5 to 100 mg/kg/day, and serum clofazimine levels were measured. In both experiments, isoniazid was used as the positive control. RESULTS: In vitro, clofazimine, at any concentration tested, did not exhibit bactericidal activity during the first week of exposure; however, in the second week, it exhibited concentration-dependent antimicrobial activity. In vivo, clofazimine, at any dose administered, did not exhibit bactericidal activity during the first week, and limited antimicrobial activity was observed during the second week of administration. While serum clofazimine levels were clearly dose dependent, the antimicrobial activity was not significantly related to the dose administered. CONCLUSIONS: Our data suggest that clofazimine's delayed antimicrobial activity may be due more to its mechanism of action rather than to host-related factors.
引用
- Ammerman NC, Swanson RV, Tapley A, et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2016. PMID: 27798204. doi:10.1093/jac/dkw417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。